Related Experiment Videos

RAGE and its emerging role in the pathogenesis of Parkinson's disease

Xiuli Jiang1, Xiaoli Wang1, Miao Tuo1

  • 1Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, China.

Neuroscience Letters
|February 26, 2018
PubMed

Insights

Receptor for advanced glycation end products (RAGE) is implicated in Parkinson's disease (PD) pathogenesis. Targeting RAGE may offer new therapeutic strategies for treating PD and related neurodegenerative conditions.

Area of Science:

  • Neuroscience
  • Immunology
  • Molecular Biology

Background:

  • Receptor for advanced glycation end products (RAGE) is an immunoglobulin superfamily receptor involved in numerous human diseases.
  • RAGE plays roles in cell processes including neuroinflammation, apoptosis, and autophagy, and is expressed in the central nervous system (CNS) by neurons, microglia, and vascular cells.

Purpose of the Study:

  • To review the role of RAGE in Parkinson's disease (PD) pathogenesis.
  • To highlight anti-RAGE strategies as potential treatments for PD.

Main Methods:

  • Review of existing literature on RAGE function and its involvement in neurodegenerative diseases.
  • Analysis of studies investigating RAGE expression in PD patients and animal models.

Main Results:

  • RAGE activation leads to signaling cascades, NF-κB activation, increased cytokine expression (TNF-α, IL-1), and reactive oxygen species (ROS) generation, contributing to neuron death.
  • RAGE is highly expressed in PD patients, and its ablation protects dopaminergic neurons in MPTP-treated mice.

Conclusions:

  • RAGE is a significant factor in PD pathogenesis.
  • Targeting RAGE presents a promising therapeutic avenue for PD treatment.

Related Concept Videos